8-K current report · filed Jul 17, 2026

Organon & Co (OGN) 8-K Current Report: July 17, 2026

Item 8.01OGN overview

Short answer

Organon & Co (OGN) filed an 8-K current report with the SEC on July 17, 2026 reporting Item 8.01 (Other Events). Merger litigation seeks to delay July 23 stockholder vote and compel further proxy disclosures.

Organon & Co 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Merger litigation seeks to delay July 23 stockholder vote and compel further proxy disclosures
  • Organon voluntarily supplemented its proxy to reduce litigation and transaction-delay risk, while denying wrongdoing
  • Preliminary Sun Pharma synergy estimate: approximately $700 million across commercial, procurement, R&D and corporate functions
  • Updated projections show 2026 revenue $6,252 million, Adjusted EBITDA $1,894 million and unlevered free cash flow $1,010 million
  • March 31 net debt $7,530 million and estimated adjusted LTM EBITDA $1,832 million, highlighting meaningful transaction leverage

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Organon & Co 8-K filings

Get the next OGN 8-K as it lands

Follow OGN for push alerts, or ask the research agent what this filing means.